Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: An updated systematic review and meta-analysis

Future Oncology

Volumn 10, Issue 12, 2014, Pages 1981-1992

  Abdel Rahman, Omar ^a   Fouad, Mona ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

bleeding; cardiovascular toxicities; hypertension; left ventricular dysfunction; meta analysis; myocardial ischemia; sorafenib

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

BLEEDING; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOLID TUMOR; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; NEOPLASMS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; CARDIOTOXICITY; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RISK FACTORS;

EID: 84922681694     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.42     Document Type: Review

References (37)

1. Cascinu S, Berardi R, Sobrero A et al. Sorafenib does not improve efficacy of chemotherapy in advanced pancreaticcancer: aGISCAD randomized Phase II study. Dig. Liver Dis. 46(2), 182-186 (2014).
2. Marampon F, Gravina GL, Popov VM et al. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. Int. J. Oncol. 44(1), 285-294 (2014).
3. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25-34 (2009).
4. Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised Phase 3 trial. Lancet Oncol. 14(6), 552-562 (2013).
5. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
6. Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J. Egypt. Natl Canc. Inst. 25(4), 165-171 (2013).
7. Abdel-Rahman O. Exploring Systemic Options For Advanced Hepatocellular Carcinoma (1st Edition). Lambert Academic Publishing, Saarbrücken, Germany (2013).
8. Abdel-Rahman O, Elsayed Z. Combination trans arterial chemoembolization (tace) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig. Dis. Sci. 58(12), 3389-3396 (2013).
9. Bayer pharma, Nexavar® prescribing information. Bayer Pharmaceuticals, Germany. http://univgraph.com
10. Moher D. Liberati A. Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62(10), 1006-1012 (2009).
11. National Cancer Institute. Common toxicity criteria. http://ctep.cancer.gov
12. Herzog TJ, Scambia G, Kim BG et al. A randomized Phase II trial of maintenance therapy with sorafenib in front-line ovarian carcinoma. Gynecol. Oncol. 130(1), 25-30 (2013).
13. Kudo M, Imanaka K, Chida N et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur. J. Cancer 47(14), 2117-2127 (2011).
14. Gradishar WJ, Kaklamani V, Sahoo TP et al. A double-blind, randomised, placebo-controlled, Phase IIb study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur. J. Cancer 49(2), 312-322 (2013).
15. Gonçalves A, Gilabert M, François E et al. BAYPAN study: a double-blind Phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann. Oncol. 23(11), 2799-2805 (2012).
16. McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized Phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol. 26(13), 2178-2185 (2008).
17. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
18. Scagliotti G, Novello S, von Pawel J et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol. 28(11), 1835-1842 (2010).
19. Spigel DR, Burris HA 3rd, Greco FA et al. Randomized, double-blind, placebo-controlled, Phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 29(18), 2582-2589 (2011).
20. Paz-Ares LG, Biesma B, Heigener D et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 30(25), 3084-3092 (2012).
21. Baselga J, Segalla JG, Roché H et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J. Clin. Oncol. 30(13), 1484-1491 (2012).
22. Margolin KA, Moon J, Flaherty LE et al. Randomized Phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin. Cancer Res. 18(4), 1129-1137 (2012).
23. El-Khoueiry AB, Ramanathan RK, Yang DY et al. A randomized Phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastaticpancreatic cancer. Invest. New Drugs. 30(3), 1175-1183 (2012).
24. Gridelli C, Morgillo F, Favaretto A et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized Phase II study. Ann. Oncol. 22(7), 1528-1534 (2011).
25. Abou-Alfa GK, Johnson P, Knox JJ et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304(19), 2154-2160 (2010).
26. Procopio G, Verzoni E, Bracarda S et al. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. Ann. Oncol. 24(12), 2967-2971 (2013).
27. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 327(7414), 557-560 (2003).
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin. Trials 7(3), 177-188 (1986).
29. Yoshiji H, Kuriyama S, Yoshii J et al. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 39, 1517-1524 (2004).
30. Abdel-Rahman O, Abdelwahab M, Shaker M et al. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. J. Egypt. Natl Cancer Inst. 26(1), 9-13 (2014).
31. Abdel-Rahman O, Abdelwahab M, Shaker M et al. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med. Oncol. 30(3), 655 (2013).
32. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
33. Abdel-rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit. Rev. Oncol. Hematol. 91(1), 1-8 (2014).
34. Choueiri TK, Schutz FA, Je Y et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J. Clin. Oncol. 28(13), 2280-2285 (2010).
35. Schutz FA, Je Y, Richards CJ, Choueiri TK et al. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J. Clin. Oncol. 30(8), 871-877 (2012).
36. Sonpavde G, Je Y, Schutz F et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit. Rev. Oncol. Hematol. 87(1), 80-89 (2013).
37. Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J. Hum. Hypertens. 27(10), 601-611 (2013).